Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics-guided rivaroxaban dosing in isolated distal deep vein thrombosis (Han Chinese)
ChiCTR2400094702Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in deep vein thrombosis (DVT) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Recurrent venous thromboembolism and Incidence of major bleeding. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR2400094702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094702.